Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
Hoffmann-La Roche
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
ImmunityBio, Inc.
University of California, Irvine
M.D. Anderson Cancer Center
University of Nebraska
Spanish Breast Cancer Research Group
Rutgers, The State University of New Jersey
University of Alabama at Birmingham
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
SCRI Development Innovations, LLC
Novartis
NSABP Foundation Inc
Massachusetts General Hospital
Dana-Farber Cancer Institute
Brown University
NSABP Foundation Inc
Yale University
Eli Lilly and Company
Translational Oncology Research International
Gilead Sciences
Hoffmann-La Roche
Central European Cooperative Oncology Group
Celgene
Celgene
Celgene
University of Alabama at Birmingham
Brown University
Case Comprehensive Cancer Center
University of California, Irvine
Stanford University
Hoffmann-La Roche
Dana-Farber Cancer Institute
University of Washington
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
Hoffmann-La Roche
Hoffmann-La Roche
Hoosier Cancer Research Network
NSABP Foundation Inc
Loyola University
National Cancer Institute (NCI)
SWOG Cancer Research Network
University of Miami